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Abbreviations: 
ASB acute sickness behaviour, BMI body mass index, CAMs  complementary and 
alternative medicines, CDC Centers for Disease Control, cDNA copy deoxyribonucleic 
acid, CFS chronic fatigue syndrome, CNS central nervous system, DSM IV diagnostic 
statistical manual 4th edition, HADS Hospital Anxiety and Depression Scale, HR heart 
rate, IFN interferon,  IL interleukin, IPAQ International Physical Activity Questionnaire, 
LOQ lowest level of quantification, mRNA, messenger RNA, ME myalgic 
encephalomyelitis, PA physical activity,  PCR polymerase chain reaction, RNA 
ribonucleic acid, RPE rate of perceived exertions, SCID Standardised Clinical Interview 
for DSM IV, SD standard deviation, SDS Sequence Detection System (SDS),  SF36 
Short Form 36 question version, SSRI  selective serotonin reuptake inhibitors, TCAs  
tricyclic antidepressant, TGF transforming growth factor, TNF tumour necrosis factor, 
TLR4 toll-like receptor 4 reuptake inhibitors, VO2 volume of oxygen. 
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SUMMARY  
Chronic fatigue syndrome (CFS) is characterized by fatigue after exertion. A 
systematic review suggested that transforming growth factor beta (TGF-β) 
concentrations are often elevated in cases of CFS when compared to healthy 
controls. This study attempted to replicate this finding, and investigate whether 
post-exertional symptoms were associated with altered cytokine protein 
concentrations and their RNA in CFS patients. 
Twenty-four patients fulfilling Centers for Disease Control criteria for CFS, but 
with no comorbid psychiatric disorders, were recruited from two CFS clinics in 
London, UK. Twenty-one healthy, sedentary controls were matched by gender, 
age, and other variables. Circulating proteins and RNA were measured for TGF-
β, TNF, IL-8, IL-6 and IL-1β. We measured six further cytokine protein 
concentrations (IL-2, IL-4, IL-5, IL-10, IL-12p70, and IFN-γ). Measures were 
taken at rest, and before and after both commuting and aerobic exercise. 
CFS cases had higher TGF-β protein levels compared to controls at rest (median 
(quartiles) = 43.9 (19.2, 61.8) versus 18.9 (16.1, 30.0) ng/ml) (p = 0.003), and 
consistently so over a nine-day period. However, this was a spurious finding due 
to variation between different assay batches.  
There were no differences between groups in changes to TGF-β protein 
concentrations after either commuting or exercise. All other cytokine protein and 
RNA levels were similar between cases and controls. Post-exertional symptoms 
and perceived effort were not associated with any increased cytokines.  
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We were unable to replicate previously found elevations in circulating cytokine 
concentrations, suggesting that elevated circulating cytokines are not important 
in the pathophysiology of CFS.
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Introduction 
Chronic fatigue syndrome (CFS) is an established condition of chronic and disabling 
fatigue and associated symptoms, which is not caused by an obvious medical disease 
or psychiatric illness [1,2]. Some authors believe that myalgic encephalomyelitis (ME) 
is a different illness, whereas others believe that ME is synonymous with CFS. The 
prevalence is between 0.2 and 2.6%, depending on definition [2]. The most 
characteristic symptoms of sufferers are fatigue and malaise that are brought on by 
minimal exertion [1]. The aetiology and pathophysiology of CFS are essentially 
unknown [2]. The illness can be precipitated by certain infections, but we do not know 
why only a small proportion of people go on to develop CFS [2]. 
The symptoms of CFS are similar to those of acute sickness behaviour (ASB) [3]. 
ASB has been found to be associated with pro-inflammatory cytokine concentrations, 
which are themselves associated with the individual symptoms of ASB [4]. Changes 
in certain cytokines, such as TGF-β, may induce symptoms or behaviour similar to 
CFS [5]. The similarity between the symptoms of CFS and ASB and the effects of 
some cytokines, along with the commonly observed onset after infections, has led to 
the hypothesis that abnormal cytokine regulation may be important in CFS 
pathophysiology [5, 6, 7]. There have been three systematic reviews of the role of the 
immune system in CFS [8, 9, 10]. The cytokines that have most often been measured 
in patients at rest include IL-1β, TNF and IL-6 [10]. No significant differences between 
cases and controls in protein levels of these cytokines were found in between 75% 
and 80% of studies [10]. The most consistent finding in five of eight case controls 
studies was that circulating TGF-β was elevated at rest [10]. 
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Apart from the criticisms of using different methods and not considering confounders 
[8, 9, 10], such as body mass index (BMI), the other problem with measuring baseline 
cytokine levels without behavioural stimulation is that this does not test whether 
abnormal cytokine release is associated with the characteristic symptom of post-
exertional malaise. Our pilot study showed that ordinary physical activity (commuting) 
was associated with significantly elevated plasma TGF-β protein concentrations, and 
that aerobic exercise was associated with significantly elevated serum tumour 
necrosis factor (TNF) protein concentrations in CFS cases compared to healthy 
controls [11].  
One systematic review, of 23 case control studies of immune changes with exercise 
in CFS, found no evidence to support cytokine changes with exercise [9]. They did, 
however, find that gene expression (mRNA) was elevated for IL-10 and toll-like 
receptor 4 (TLR4), as well as evidence to support complement 4a split product 
activation [9]. One study, which was included in this review, also found an association 
between the level of mRNA, measured as the area under the curve, for both IL-10 
and TLR4 and post-exercise symptom exacerbation [12]. A case control study, not 
included in this review, found no differences in IL-10 receptor mRNA between groups 
[13]. 
Blundell and colleagues systematically reviewed 38 case control studies, which 
included studies specifically examining evidence for cytokine changes with exercise 
[10]. Only three cytokines had been measured in five or more studies, (IL-6, IL-1β, 
and TNF), with the large majority of studies showing no differences between cases 
and controls. Two out of two studies found elevated IL-2 after exercise, and a further 
 7 
two out of two studies found elevated TGF-β after exercise, but no association with 
post-exertional symptoms [10]. 
This research, highlighting the possible relevance of TGF-β, TNF, IL-6 and IL-1β, as 
well as the literature on exercise and cytokine response in the healthy population, in 
which TNF, IL-1, IL-6, IL-10 and IL-8 seem to be involved [14], informed our choice 
of hypothesised cytokine proteins (IL-6, IL-8, TNF and TGF-β) for this study. By also 
measuring the RNA of these four hypothesised cytokines (along with IL-1β as a 
correlation control for detectable protein vs RNA) we were able to explore their 
biological pathway. It is possible that the complex temporal regulation of cytokine 
expression during physical activity may not be fully reflected in simple blood 
concentrations [15]. Although there is little evidence for this [16], it is possible that 
some cytokines may remain cell surface bound so bio-active and peripheral levels 
may not be fully representative [17, 18]. Measuring RNA alongside proteins allows us 
to determine cytokine gene expression, allowing a greater understanding of cytokine 
involvement in pathology and physiological processes. 
The aim of this study was to test the hypothesis that cytokines are excessively 
expressed as a response to physical activity in patients suffering from CFS. Our 
hypotheses were as follows: 
1. Aerobic exercise and commuting to hospital induce greater increases in 
serum protein concentrations of transforming growth factor (TGF-β), tumour 
necrosis factor (TNF), interleukin 6 (IL-6), interleukin 8 (IL-8) and their RNA 
in cases of CFS compared to healthy sedentary controls. 
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2. Perceived effort with exercise and post-exercise increases in malaise, fatigue 
and pain are associated with increased serum protein concentrations of pro-
inflammatory cytokines including TNF, IL-8, IL-6, and their RNA in cases but 
not controls. 
3. Increased post-commuting malaise, fatigue and pain are associated with an 
increased serum protein concentration of TGF-, and its RNA in cases, but not 
controls. 
4. Depressed and anxious mood, physical deconditioning and sleep disturbance 
are mediating factors in the increased protein concentrations of the cytokines 
TNF, IL-6, IL-8, and TGF-β in cases. 
 
Materials and Method 
CFS patients  
Consecutive new adult (aged 16-65) outpatient attenders at the CFS clinics at St 
Bartholomew’s and the Royal Free hospitals in London, UK, were invited to take part 
in this study if they met inclusion criteria. No patient from our original pilot study was 
recruited into this study [11]. Patients with CFS diagnosed by Centers for Disease 
Control (CDC) (international) criteria [1], with the modification of not having any 
concurrent co-morbid psychiatric disorder, were studied. We excluded those with 
comorbid psychiatric disorders (with the exception of simple phobias) in order to 
reduce the heterogeneity of the patient sample and reduce confounders, since certain 
(non-excluding) comorbid psychiatric disorders such as non-melancholic depressive 
disorder may also be associated with abnormal cytokine concentrations [19]. We 
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used the Standardised Clinical Interview for DSM IV (SCID) to screen patients and 
controls for psychiatric disorders [20]. We excluded participants (patients and 
controls) if they had regularly been taking any prescribed medications in the past two 
weeks that might affect the immune system or exercise challenge. We allowed the 
use of selective serotonin reuptake inhibitors, tricyclic antidepressants and 
paracetamol. Participants could have certain co-morbid medical conditions if in 
remission (e.g. hypothyroidism if biochemically euthyroid on thyroxine replacement 
therapy) [1]. Medications taken in the previous week were recorded and examined in 
the analysis as potential confounders. We chose to recruit from secondary care, since 
our pilot data were from this population and because it allowed for ease of recruitment 
to test our primary hypotheses. 
 
Healthy controls 
The comparison group were 21 healthy but sedentary volunteers (engaging in 
moderate-intensity exercise or physical activity, for up to 20 minutes in a single 
episode, less than once a week). We group matched controls by age (+/- 5 years), 
sex, body mass index (+/- 2.5) and distance they lived from the hospital (+/- 2 miles). 
We recruited the healthy volunteers through the CFS patients and patient groups 
(healthy but sedentary friends or relatives that were not blood relatives), the 
participating hospitals and medical schools (employees or their friends or family), and 
people living or working locally. We used emails, posters in waiting rooms, local 
advertising in bulletins, newsletters and newspapers to target potential healthy 
volunteers. Health status was assessed with a brief interview by the researcher, with 
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standard questions, excluding all those with a current infection, chronic disease, 
taking medicines, or psychiatric disorder as above. 
 
Study design and ethics 
This was a 16-day study whereby participants (both patients and controls) attended 
the hospital on four occasions, with blood samples taken over a 9 day period from 
day 7 to day 16. A baseline assessment on day 1 mainly comprised obtaining written 
informed consent, self-completion of questionnaires and the SCID [20]. A “commuting 
challenge” was completed on day 7, which included the participant having blood 
drawn at home after a night’s sleep/rest, before they rose from their bed. Another 
blood sample was taken when they arrived at the hospital on the same day after 
commuting from their home to the hospital. An aerobic exercise challenge was 
completed on day 14. On this day blood was drawn before, immediately after, and 3 
hours after exercise. On day 16 (two days after the exercise) a final blood sample 
was taken at the hospital and follow-up questionnaires were administered. 
Participants were studied 48 hours after the exercise, rather than 72 hours afterwards 
as in the pilot study [11], since our clinical impression suggested that CFS patients 
perceive most post-exertional symptoms at this time. 
Participants’ blood samples were drawn between 9am and 2pm, except for the 
sample taken whilst resting at home before commuting (day 7) which was often 
earlier, and a three-hour post-exercise sample (day 14) which was often later. 
Samples were obtained at a fixed time after arrival at the hospital (15 minutes), and 
in a fixed sequence (protein assays followed by RNA) from ante-cubital venous 
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puncture. All participants were required to have eaten breakfast prior to their arrival 
at each of their hospital appointments, but to have abstained from caffeinated drinks 
that morning. Menstrual phase was recorded in premenopausal female subjects. 
Since appointments spanned 16 days it was not possible to co-ordinate testing during 
one (luteal) phase of the cycle. 
Normal activities at home were resumed between appointments, with seven days 
considered as giving sufficient time for participants to re-establish baseline cytokine 
concentrations after each hospital visit; gene expression usually returns to normal 24 
hours after exercise in healthy people [21]. Symptom exacerbations were rare a week 
after hospital travel in the pilot study [11]. 
To maximise participant retention without influencing the validity of the results we 
allowed some flexibility with appointment days. If a participant was unable to attend 
an appointment on the scheduled day, they were allowed to attend on the day before 
or the day after. However, the final appointment always took place two days after the 
exercise challenge, and the home visit always occurred on the same day as the 
commuting challenge. 
This study was approved by the London Bridge Research Ethics committee 
(11/LO/1572). Written informed consent was obtained from all participants who were 
paid travel expenses. Healthy volunteers were also paid £10 for each of their four 
hospital visits. 
 
Questionnaires 
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On days 1 and 16 of the study, fatigue was measured with the 11 item Chalder fatigue 
questionnaire [22], perceived physical disability was measured using the Short Form 
(SF-36) physical function sub-scale [23], self-rated mood was measured with the 
Hospital Anxiety and Depression Scale (HADS) [24] and sleep disturbance was 
measured using the Jenkins sleep scale [25]. The International Physical Activity 
Questionnaire (IPAQ) was used on Day 1 to measure physical activity participation in 
the past week [26]. The McGill present pain intensity scale was used to measure pain 
intensity on day 1, before and after travelling on day 7, before and after exercise on 
day 14 and on day 16 [27]. Ad hoc self-rated five item Likert scales were used to 
measure the effect of activity/exercise on delayed fatigue, pain and malaise (unwell) 
at the same times. Response options ranged from ‘strongly disagree’ through ‘neither 
agree nor disagree’ to ‘strongly agree’. Fear of exercise was determined on day 14 
using the Tampa scale for kinesiophobia for fatigue [28], with healthy volunteers being 
asked to recall the last time they felt extreme tiredness that was not related to a 
medical condition, being pregnant, or dehydration. 
 
Exercise challenge 
The aerobic exercise challenge used a friction-loaded cycle ergometer (Monark 808, 
Sweden). The cycle ergometer was chosen in preference to a treadmill because it 
requires limited familiarisation, was used in our pilot study, and is generally perceived 
by participants as less distressing. All subjects completed a five-minute familiarisation 
period of unloaded cycling at a cadence of 60 rev.min-1. After the familiarisation 
period, the subjects fulfilled a sub-maximal exercise protocol. We chose this protocol 
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because in our pilot study we found no statistically significant differences in either 
subjective reactions or immune variables between the 70% sub-maximal test and the 
100% maximal test [11]. The workload was increased by 30 Watts every 3 minutes 
until a heart rate (HR) equal to 70% of age predicted maximum HR (192 – 0.007 x 
age in years2) was achieved [29], to within 10 beats per minute. After this point, the 
participants continued to exercise at this workload for 20 minutes or until volitional 
exhaustion. Volitional exhaustion was considered to have occurred if the subject was 
no longer able to maintain cadence within 10 rev.min-1 of the required 60 rev.min-1, in 
spite of encouragement. 
During the exercise challenge participants were asked to breathe through a 
mouthpiece connected to a system of open circuit spirometry with a nose-clip 
preventing air escaping. Expired gases were analysed breath-by-breath throughout 
the exercise by a cardiorespiratory analyser (CPX/D, Medical Graphics Inc., USA), 
calibrated according to the manufacturer’s instructions prior to each test. The oxygen 
consumption (V̇O2 ml.kg.min-1) was averaged every 30 seconds with peak V̇O2 
determined as the highest V̇O2 value obtained. Heart rate (HR) was also recorded 
every five seconds using a HR monitor (POLAR Electro, Finland). The highest 30-
second average HR (b.min-1) was deemed to be the peak HR. The exercise challenge 
duration (seconds) was also recorded. The original Borg scale of rating of perceived 
exertion (RPE) was self-rated throughout the exercise test and immediately after the 
exercise was completed [30]. The RPE score at 70% of peak HR was used as the 
split-point for the analysis of perceived effort in hypothesis 2, since all participants 
reached this point. 
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Laboratory assays 
At each bleed, we took 15mls of blood in three tubes: 10ml for serum proteins and 
5ml for RNA extraction. The samples were sent to the laboratory and would have 
arrived at the latest the following morning (if taken in the afternoon). One tube was 
centrifuged immediately for storage, the second was stored at ambient room 
temperature for 24 hour and then centrifuged. All samples were then frozen and 
stored at -70 0C until analysed in three batches. The RNA tube was immediately 
stored as it was at -80oC, in line with the manufacturers guidance. All laboratory work 
was completed by laboratory staff blind to group membership. Eleven cytokines (IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TGF-β, TNF and IFN-γ) were measured 
on the basis that they would either be expected to be abnormally regulated in CFS 
after exertion and reflect a broad range of cell types, or that they had been previously 
shown to be elevated in CFS in some studies [9,10]. Serum protein concentrations of 
TGF-β were analysed by ELISA methodology according to manufacturer’s 
instructions (R&D systems). The TGF-β samples were analysed in three batches by 
two laboratory technicians, with one technician analysing the first batch of samples in 
2009 and the other technician analysing the second and third batches of the samples 
in 2011. As part of the standard operating procedure, the serum was centrifuged at 
2,500 rpm for 10 minutes. This is important in that TGF-β is released from platelets 
in greater quantities with faster centrifuging speeds. The remaining cytokines were 
analysed in three batches, separately from TGF-β, and were determined using 
multiplex cytokine bead array as per the manufacturer’s instructions (BenderMed 
Systems). We measured all the cytokines at all time points and have reported values 
as picograms per millilitre (pg/ml). Lowest levels of quantification (LOQ), below which 
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each cytokine in the assay were considered undetectable are shown in Table 1, and 
these values are used where a value was undetectable. For quality assurance, in the 
first batch, where an analyte looked to be a possible outlier we re-analysed the 
sample and took the mean of the two assays. These values did not alter the results 
so we did not repeat this with the remaining batches. We analysed RNA for five of 
the cytokines (IL-1β, IL-6, IL-8, TGF- β and TNF), for which we report relative 
expression values. 
In our pilot study [11] we analysed platelet poor plasma when investigating the 
circulating levels of TGF-β. TGF-β are synthesised as precursor forms which are 
biologically latent; the precursor form is cleaved by serine proteases and following 
dissociation from the latency peptide becomes biologically active [31]. Since the latent 
pool is bioavailable following protease cleavage, TGF-β assessment should be of 
active and latent acid-activated subsets. The use of platelet poor plasma has been 
largely superseded by serum based assays, following an understanding that platelet 
derived (and usually non-bioavailable) TGF-β is sequestered in the matrix of the clot 
in serum [32]. There is less experimental variation in the coagulation of serum in 
serum separator tubes than in producing platelet poor plasma [33]. TGF-β protein 
levels in serum and plasma are the same (when plasma is optimally prepared) and 
so serum was employed as the preferred substrate in this study [32]. 
 
Sample quality control, cDNA synthesis, endogenous control selection & qPCR 
RNA purity and concentration were measured by the NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific Inc), and RNA integrity was 
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evaluated using the Agilent Bioanalyzer 2100 (Agilent Technologies). Initial 
quality control showed significant DNA contamination of the RNA samples, 
characterised by masking of the 28s peak on the Bioanalyzer traces. 
Contaminating DNA was removed using an in-solution DNase treatment, followed 
by concentration and clean-up using Qiagen RNEasy MinElute columns 
(Qiagen). RNA concentration and integrity were re-measured post-DNAse 
treatment. cDNA was synthesised using 200ng of total RNA in a reaction volume 
of 20uL using the High-Capacity RNA-to-cDNA Master Mix kit (Life 
Technologies). Resulting cDNA was diluted 1:10 for use in subsequent qPCR 
reactions. 
The most appropriate endogenous control assays from a panel of 6 reference 
genes (18S, β2M, ATP5β, EIFA42, GAPDH and UBC) were selected after qPCR 
analysis of 10 representative RNA samples from the study using all 6 assays. 
The geNorm software package was used to assess the stability of the 6 genes in 
this sample set. The two most stable genes, ATP5β and GAPDH, were selected 
to run alongside the assays of interest in order to evaluate relative expression of 
the candidate genes [34]. Primers and probes used for qPCR were available as 
inventoried Taqman® assays from Life Technologies (Table 2) and PCR 
reactions were carried out using the Taqman Universal PCR Master Mix (Life 
Technologies) in a 10uL reaction volume. Thermal cycling was performed using 
the 7900HT Sequence Detection System (SDS) (Applied Biosystems), and PCR 
program 50°C for 2 mins, 95°C for 10 mins followed by 40 cycles of 95°C for 10s 
and 60°C for 1 min. Each reaction included a no-template control as a negative 
sample, and each cDNA sample was run in triplicate. 
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Relative expression compared with GAPDH and ATP5B was generated using the 
2-ΔΔCt method, using cycle threshold values (Ct) generated automatically by the 
7900HT SDS software. Standard deviations and coefficients of variation were 
calculated for each set of triplicate data, and any outliers were removed. 
 
Statistical Analysis 
Not detectable cytokine protein concentrations were approximated as the lowest level 
of quantification (LOQ) value (Table 1) for the purpose of the analyses. Testing the 
hypotheses required non-parametric statistical testing using the Mann-Whitney test 
as the majority of data were not normally distributed. For hypothesis 1 we first 
compared absolute cytokine protein values, and their RNA at each time point between 
groups and then the difference between groups in any relative change (delta) in the 
values from baseline to post commuting/exercise. We also used the Wilcoxon signed 
rank test to determine any differences over time within groups. 
For the across-group analyses for responses to commuting in hypothesis 1, we 
compared post-commuting to pre-commuting cytokine protein concentrations and 
their RNA, and for the response to aerobic exercise we compared pre-exercise to: 
immediately post-exercise, 3-hours post-exercise and 2-days post-exercise. Where 
necessary we adjusted the analyses for multiplicity using a Bonferroni adjustment. 
Analysing the patients and controls separately, we tested hypothesis 2 using Mann-
Whitney tests to determine any differences in the relative change in cytokine protein 
and RNA levels between those reporting an RPE during the exercise test that was 
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above or below the group median value. We compared: pre-exercise to: immediately 
post-exercise, 3-hours post-exercise and 2-days post-exercise. We used the same 
analyses to determine any differences in cytokine protein and RNA levels for those 
reporting increased fatigue, pain and malaise after exercise and to determine any 
differences in TGF-β protein and RNA levels for those reporting increased fatigue, 
pain and malaise after commuting compared to those who reported no change 
(hypothesis 3). 
Analyzing only the patients, we tested hypothesis 4 using Spearman's rank 
correlation coefficient to determine the relationships between cytokine protein level 
(when significantly elevated) and potential mediating factors of depression, anxiety, 
sleep disturbance and physical deconditioning (using time spent active during a week, 
time exercising during the exercise test and maximum power output achieved within 
the exercise test). We used the cytokine protein values two days after exercise since 
our clinical impression suggested CFS patients perceive most post-exertional 
symptoms at this time. As a post-hoc analysis we examined the distribution of TGF-
β protein in the cases and found it to be bimodal in its distribution.  
As an exploratory analysis, we examined all additional seven cytokine protein levels 
(IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12p70 & IFN-γ) using the Mann-Whitney test. We first 
compared absolute cytokine protein values at each time point between groups. If 
there were sufficient detectable data we then looked at the difference in the relative 
change (delta) scores from pre to post commuting and from pre-exercise to 
immediately, 3 hours, and two days, after the exercise between groups. Since all 
cytokine proteins were measured six times, we corrected when necessary for multiple 
measures using a Bonferroni adjustment. 
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Confounders 
To further determine whether the results were influenced by possible confounders, 
we adjusted significant findings for assay batch technician, gender, contraceptive pill 
use, whether taking TCAs, smoking status, use of antihistamines, homeopathy, 
vitamins and minerals, or other complementary or alternative medicines (CAMs), age, 
BMI, day of menstrual cycle at time of blood test, duration of CFS (> or < 3 years) 
[35], time spent walking in one week, time spent in bed in a week, perceived effort of 
the exercise test (RPE at 70% peak HR), fear of having blood taken, sleep 
disturbance [25], and levels of anxiety and depression [24]. We only explored 
cytokines protein and RNA that showed significant differences between groups and 
we used cytokine values 2-days after the exercise challenge. We modelled 
significantly associated (p ≤ 0.10) confounders using appropriate regression models. 
 
Power analyses 
We used our pilot data to guide our calculation and took the significance level as 0.05 
and the power of the study at 80%. In order to detect a difference in baseline TGF-β 
protein between cases and controls of 0.35 ng/ml with an estimated standard 
deviation (SD) of 0.31 we needed 14 cases in each group. Due to non-normality of 
the data we upwardly adjusted the sample size to 16 in each group [36]. When we 
repeated the power calculations using the pilot data for TGF-β protein three days after 
exercise and the mean (SD) difference in TGF-β protein before and after travelling to 
hospital, the number of samples required was similar. We increased the sample sizes 
 20
to 24 in each group in order to allow our hypothesis-generating work. Since there 
have been no previous studies of the associations between cytokine protein levels 
and dependent variables such as post-exertional symptoms or activity, this part of the 
study was exploratory. 
 
Results 
A total of 24 patients (cases) and 21 controls were recruited into the study. Gender, 
age, smoking status, distance they lived from the hospital, amount of physical activity 
they undertook and time spent sitting were not significantly different across groups 
(Table 3). There were no statistically significant differences in the use of 
antidepressants, antihistamines, the oral contraceptive pill and thyroxine, but cases 
were generally more likely to be taking vitamins, minerals or other complementary 
and alternative medicines (CAMs) and spent more time in bed each night (Table 3). 
The median (quartiles) duration of illness in the cases was 61 (37, 122) months. As 
expected, cases had significantly worse scores for fatigue, physical functioning, mood 
(anxiety and depression), pain and sleep measures than controls (table 4).  
Median (quartiles) rating of perceived exertion (RPE) measured at 70% of predicted 
peak HR, during the exercise challenge, was significantly higher in cases (15 (14, 
17)) compared to controls (13 (12.5, 13)) (p = 0.002) (table 5). Furthermore, four times 
as many cases had an RPE >14 (median for all subjects) at 70% of their predicted 
peak HR during the exercise test (16 vs. 4; p = 0.001). Cases spent significantly less 
time cycling during the exercise test (p = 0.027), but showed a similar peak V̇O2 
(ml.kg.min-1) and peak heart rate (bpm). 
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Table 6 shows baseline levels of all cytokines protein and RNA measured at rest in 
bed, before rising, on day 7. There was no significant difference between groups in 
the number of detectable versus undetectable levels in any of the cytokines (in 
analysis of the protein or RNA results).  
 
Hypothesis 1 – Increases in cytokines in cases compared to controls 
After a Bonferroni adjustment for multiple-testing (x6), TGF-β protein levels were 
significantly elevated in cases compared to controls at rest (median = 43.9ng/ml vs 
18.9 ng/ml; p = 0.003), after commuting (median = 56.9ng/ml vs 21.4ng/ml; p = 0.002) 
and 2-days post-exercise (median = 49.1ng/ml vs 21.9ng/ml; p = 0.007) (Fig. 1). The 
changes in TGF-β protein concentrations due to either commuting or exercise were 
not significantly different between the groups although there was a significant 
increase pre to post commuting in the cases (p = 0.003) but not pre- to post-exercise. 
After a Bonferroni adjustment for multiple-testing, IL-8 protein levels were not 
significantly higher in the cases compared to controls at any time point. Values for IL-
6 and TNF proteins were not significantly higher in the cases compared to controls at 
any time point.  
No RNA values were significantly different between cases and controls at any time 
point from pre-commuting to 2-days post exercise. Neither commuting nor exercise 
induced greater relative increases in concentrations of RNA of TGF-β, TNF, IL-8 or 
IL-6, in cases compared to controls.  
 
Hypothesis 2a – perceived effort with exercise 
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Cases that reported an effort (RPE) during the exercise above the median did not 
demonstrate significantly greater increases in values for protein or RNA for TNF, IL-
8 or IL-6 either immediately, 3-hours or 2-days after the exercise compared to those 
reporting a lower effort with exercise. 
 
Hypothesis 2b – pain, malaise and fatigue with exercise 
Significantly more cases, compared to controls, agreed or strongly agreed that they 
were more fatigued (19; 83% vs 1; 5%; p < 0.001), in more pain (13; 57% vs 1; 5%; 
p < 0.001), or felt more malaise (15; 65% vs 0; 0%; p < 0.001), 2-days after the 
exercise.  
Cases who agreed that their fatigue, malaise or pain increased after the exercise test 
did not have significantly greater relative changes in TNF, IL8 or IL-6 protein or RNA 
either immediately, 3 hours or 2 days after the exercise, compared to those who 
disagreed. 
 
Hypothesis 3 – post-commuting symptoms related to TGF-β 
After commuting to the hospital, neither TGF-β protein nor RNA were significantly 
increased in patients who agreed they felt more fatigue, malaise or pain after 
commuting, compared to those who disagreed. In the control group there were not 
enough data to analyse because only two participants reported feeling more fatigued 
and none reported more malaise or pain after commuting. 
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Hypothesis 4 - Potential mediators in cases 
When analysing TGF-β protein levels in cases alone, we noticed a clearly bimodal 
pattern to the data with 12 (50%) cases having consistently high values and the other 
12 having consistently low values (Fig. 2). The cut-off we used was 37ng/ml. The 
mean values for TGF-β protein levels in the ‘high TGF-β’ group were significantly 
higher than the values for the ‘low TGF-β’ group (p < 0.001) when compared after 
exercise. 
In cases, concentrations of TGF-β protein after the exercise challenge were not 
significantly associated with depressed or anxious mood, with physical 
deconditioning or sleep disturbance (data not shown). 
 
Exploratory work 
The exploratory work did not show any statistically significant differences in cytokine 
protein levels between cases and controls at any time point, and there were no 
significantly different relative changes in any of the exploratory cytokine levels 
between cases and controls after commuting or the exercise challenge. 
 
Confounders in cases and controls 
On deeper analysis of confounders, we examined TGF-β values by both assay 
batches and by the two laboratory technicians who ran the assays. We show these 
data for one of the times where there was a significant difference between groups 
(table 7). This shows that batch one TGF-β concentrations (both for cases and 
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controls) were significantly higher than the concentrations for batches 2 and 3. 
Comparing the results of the two technicians shows that technician 1 found 
significantly higher concentrations than technician 2 (patient versus patient p < 
0.001). 
Analysing cases and controls together, menstrual cycle phase, allowable medications 
and smoking status did not influence TGF-β protein levels. However, taking the oral 
contraceptive pill (OCP) (p = 0.02) having a higher depression score (p = 0.03), and 
having a sample analysed by operator 1 (p < 0.001) predicted higher levels of TGF-
β protein two days after exercise. We undertook a multiple regression analysis which 
included laboratory technician, group, OCP and depression, plus body mass index (p 
= 0.07). We used the stepwise method using transformed TGF-β protein (log e) on 
day 16 and found that laboratory technician (1 vs 2) was the only significant predictor, 
which accounted for 79% of the variance in TGF-β protein (adjusted R2 = 0.79; p < 
0.001). 
 
Summary of findings 
After correcting for multiple analyses, TGF-β protein was the only cytokine protein or 
RNA that showed significantly different values between CFS and control groups. This 
was found to be a spurious finding, explained by assay variation between laboratory 
technicians. Neither protein nor RNA concentrations of any other cytokines were 
significantly higher in cases after commuting or an exercise test.  
 
Discussion 
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In this study we investigated circulating cytokines and their RNA in patients with CFS 
at rest, after commuting, and after an acute bout of physical activity. We found no 
evidence to support our hypothesis that these activities increased cytokine levels or 
their RNA, or that they were associated with post-exertional symptoms and higher 
perceived effort of exercise that are commonly experienced by people with CFS. In 
contrast, our data showed a significant elevation in circulating TGF-β at rest and 
afterwards over the nine days of testing in patients compared to controls. Further 
analysis showed a clear bimodal distribution to TGF-β, particularly in cases. This was 
found to be an artefact, explained by a laboratory anomaly, with technician 1 finding 
consistently higher values for TGF-β in both cases and controls, compared to 
technician 2. Since there were 13 (54%) cases and only 2 (10%) controls assayed by 
technician 1, it therefore appeared as though cases were more likely to have elevated 
concentrations when analysed by summarised group. Changes in TGF-β protein 
levels due to commuting or exercise were similar in patients and controls.  
Previous studies have been criticised for not accounting for confounding factors that 
can affect cytokine concentrations [9, 10]. We measured a number of possible 
confounders and found that only laboratory variation influenced TGF-β protein levels. 
We were unable to replicate finding a difference by duration of illness [35], although 
this study had smaller numbers of patients. Contrary to some previous studies, 
including our own pilot study [11], we found no differences in concentrations of TNF 
between patients and controls. Our finding that any change in TGF-β after exercise 
was not significantly different from any change in the control group replicates previous 
work [37].  
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We cannot know whether the same laboratory variation explains the previous case 
control findings for TGF-β, but case control studies can start subject recruitment with 
cases, in order to ascertain accurate matching of controls, so any inter-batch assay 
variation might explain why it appeared that cases had different concentrations from 
controls. We were unable to ascertain the differences in laboratory processing that 
led to the differences between batches, but assume that the difference was due to 
using different centrifuge times, which might affect TGF-β release from platelets, 
leading to differences in TGF-β concentrations. Great care needs to be taken in any 
case control study where matters such as centrifuge speed and timing can determine 
release of cytokines such as TGF-β.  
This study does not rule out a role for local release of cytokines in the central nervous 
system (CNS). There is a two way relationship between the immune system and the 
CNS [3, 4]. Cytokines can cross the blood brain barrier, particularly when the blood 
brain barrier is modified by factors such as intercurrent infections or distress [38]. 
Cytokines are locally released by glial cells in the CNS, and TGF-β can cause central 
motor fatigue in animals [5, 39]. Cytokines, such as TGF-β, could thus affect the 
perception of pain and fatigue through both direct and indirect effects. There is some 
recent evidence to support neuro-inflammation in CFS/ME [40]. TGF-β appears to 
have complex effects in the brain, but may promote a pro-inflammatory state and 
disturbance of blood brain barrier function [41].  
It is known that sufficient exercise can modulate cytokines at the level of gene 
expression to protein ligand release and receptor activation, with associated local and 
systemic consequences in the healthy population [16, 42]. Although there is little 
evidence for this in patients with CFS [16, 43], it is possible that cytokines such as 
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TGF-β1 remain cell surface bound so bio-active and peripheral levels may not be fully 
represented either at rest or after exercise. By investigating RNA in this study it 
allowed us to determine the presence of such cytokine gene expression. However, 
we did not find RNA concentrations elevated in cases compared to controls with any 
of the cytokines for which it was measured, and it did not change differently between 
groups with either commuting or exercise in RNA extracted from whole peripheral 
blood. Finding no statistically significant difference in TGF-β RNA supports the 
spurious nature of the elevated TGF-β protein levels found in this study. 
This study had some limitations. With 24 cases in the patient sample it is a relatively 
small sample particularly for the number of cytokines we wished to investigate; it is 
likely that we were underpowered. Finding cases without psychiatric comorbidity, who 
were not on medicines that excluded them, was a challenge. There is good evidence 
that CFS is a heterogeneous group of conditions [44], but our sample of cases was 
too small to divide into sub-groups, which a larger study has suggested may affect 
circulating cytokine concentrations [35]. Although we tried to match on a number of 
criteria, including smoking status and those taking the oral contraceptive pill (both 
known to effect cytokine levels), it was difficult to recruit sedentary and yet healthy 
participants who were not taking any excluding medicines. This is why we were only 
able to recruit 21 controls and they had a trend towards a higher BMI, were taking 
less vitamins and spent less time in bed, all of which could have confounded inter-
group differences. In addition, because the protocol required a number of visits to the 
hospital, the CFS patients volunteering for this study would have been more 
physically able and those declining would have likely been the most disabled, leading 
to an increased risk of a type-2 error.  
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The strengths of this study include the reliability of the findings in having six measures 
of the same cytokines over nine days and testing for confounding factors such as 
taking the oral contraceptive. We also excluded participants with comorbid psychiatric 
disorders (a novel approach) that could have confounded cytokine levels, so our 
findings are more specific to CFS. We were able to analyse a good number of 
cytokines, including five in which more than one study had shown previous elevations, 
and others that had not been measured previously. We also suggest there is heuristic 
value in reporting this study, as an apparent bimodal distribution of a potential 
biomarker in CFS was found, which on a deeper analysis of confounders was found 
to be spurious. 
 
Implications for future research 
A systematic review of the association between circulating cytokines and CFS 
showed that only TGF-β was elevated in the majority of case control studies 
[10]; a finding we were unable to replicate. Another systematic review 
concluded that cytokine concentrations were not abnormal after exercise in CFS 
[9]; a finding we replicated. We suggest that circulating levels of cytokines are 
unlikely to be important in the pathophysiology of CFS. 
Conclusions 
We replicated the finding of consistently higher circulating TGF-β at rest in 
cases of CFS compared to healthy controls, but deeper analysis showed this to 
be a spurious finding, due to laboratory variation. Post-exertional symptoms and 
perception of effort with exercise were not associated with an increase in 
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circulating cytokine protein or RNA concentrations in patients with CFS. There 
have been many studies showing associations between various biomarkers and 
CFS, which have not been replicated; due caution should be taken before the 
next biomarker is reported.  
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Figure Legends 
Fig. 1. Serum protein concentrations of TGF-beta in CFS cases compared to 
controls (median scores in ng/ml); single dots represent control outliers 
 
Fig. 2. TGF-β protein concentrations in cases at each time point (ng/ml) 
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Fig. 1. Serum protein concentrations of TGF-beta in CFS cases compared to controls (median 
scores in ng/ml), single dots represent control outliers 
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Fig. 2. TGF-β protein concentrations in cases at each time point (ng/ml) 
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Table 1. List of lowest level of quantification (LOQ) for cytokine proteins 
Cytokine name Lowest level of 
quantification 
(pg/ml) 
IL-1β 4.2 
IL-2 16.4 
IL-4 20.8 
IL-5 1.6 
IL-6 1.2 
IL-8 0.5 
IL-10 1.9 
IL-12p70 1.5 
TGF-β 10.0 
TNF 3.2 
IFN-γ 1.6 
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Table 2. List of Genes and Gene Expression IDs 
Gene name Life Technologies Assay 
ID 
18S Hs99999901_s1 
β2M Hs99999907_m1 
ATP5β Hs00969567_g1 
EIFA42 Hs00756996_g1 
GAPDH Hs99999905_m1 
UBC Hs00824723_m1 
IL1β Hs01555413_m1 
IL6 Hs99999032_m1 
IL8 Hs01553824_g1 
TNF Hs00174128_m1 
TGFβ1 Hs00998133_m1 
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Table 3. Demographics and clinical data (n (%) unless otherwise stated) 
 CFS 
n = 24 
Control 
n = 21 
p value 
Age (years)a 40.3 (12.2) 39.3 (14.1) 0.81 
Gender (Female) 15 (63%) 16 (76%) 0.32 
BMI 23.2 (4.5) 25.5 (4.4) 0.08 
Distance from hospital (miles)b 6.9 (3.8, 11.0) 7.8 (6.0, 11.7) 0.26 
Taking antidepressants (SSRIs or 
TCAs) 7 (29%) 2 (10%) 0.14 
Taking antihistamines 3 (13%) 1 (5%) 0.61 
Taking thyroxine 1 (4%) 2 (10%) 0.59 
Taking the oral contraceptive pill 
(females only) 
4 (27%) 1 (6%) 0.17 
Cigarette smoker 4 (17%) 4 (19%) 1.000 
Taking vitamins, minerals and/or 
CAMs 13 (54%) 4 (20%) 0.015 
Daily mins of activity b 21.8 (7.3, 46.4) 25.0 (7.9, 40.0) 0.91 
Above recommendations for PA 10 (42%) 10 (44%) 0.69 
Time spent sitting on usual day 
(minutes) b 
600 
(458, 803) 
690 
(495, 765) 
0.91 
Time spent in bed at night 
(minutes) b 
540 
(480, 600) 
480 
(420, 480) 
0.001 
a = Mean (SD); b = Median (quartiles) 
BMI = body mass index; SSRI = selective serotonin reuptake inhibitors; TCAs = tricyclic 
antidepressant; PA = physical activity; CAMs = complementary and alternative medicines 
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Table 4. Questionnaire scores at baseline (median (quartiles)). 
 CFS 
N = 24 
Control 
N = 21 
P value 
Duration of illness (months) 60.5 (37, 122) -- -- 
Chalder fatigue score 27 (22, 30) 11 (10, 11)  <0.001 
SF-36 PF 60 (40, 75) 100 (95, 100)  <0.001 
Jenkins sleep  9 (6, 12) 4 (2, 5) <0.001 
HADS Depression 5 (4, 7) 0 (0, 1.5) <0.001 
HADS D (excluding “slowed 
down”) 
3 (1, 5) 0 (0, 1) <0.001 
HADS Anxiety 7.5 (5, 9) 3 (1.5, 7)   0.003 
McGill Pain (discomforting or 
distressing) a 
18 (75) 0 (0) <0.001 
a = n (%). SF-36 PF = SF-36 physical functioning subscale; HADS = Hospital anxiety and 
depression scale 
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Table 5. Exercise test variables (medians and quartiles). 
 CFS (n = 23) Control (n = 20) P value 
RPE Score at HR 70% peak 15 (14, 18) 13 (12, 13) p = 0.002 
RPE > median of 14 at HR 70% 
peak 
16 (70%) 4 (20%) 
p = 0.001 
Time on bike (secs) 960 (675, 1530) 1530 (1080, 1620) p = 0.027 
V̇O2 peak (ml.kg.min-1) 20.4 (16.8 to 22.2) 19.5 (14.1 to 21.2) p = 0.31 
Peak HR (b.min-1) 143 (136 to 154) 151 (145 to 159) p = 0.09 
Max Power (watts) 90 (60 to 90) 90 (60 to 90) p = 0.62 
Competed test (yes) 9 (39%) 14 (70%) p = 0.043 
RPE = rating of perceived exertion, HR = heart rate. VO2 = Volume of oxygen. 
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Table 6: Baseline cytokine (protein and RNA) concentrations at rest, (at home in bed, on day 
7) using lowest level of quantification (LOQ) for undetected values (medians and quartiles) 
 CFS (n = 24) Control (n = 21) 
Cytokine 
pg/ml 
Undetectable 
(n) 
All CFS, imputing LOQ 
for undetectable values 
a, b 
Undetectable 
(n) 
All control, imputing 
LOQ for undetectable 
values b 
IL-1β 20 4.2 (4.2, 4.2) 18 4.2 (4.2, 4.2) 
IL-2 13 16.4 (16.4, 66.5) 17 16.4 (16.4, 16.4) 
IL-4 17 20.8 (20.8, 23.2) 15 20.8 (20.8, 20.8) 
IL-5 21 1.6 (1.6, 1.6) 16 1.6 (1.6, 1.6) 
IL-6 24 1.2c 18 1.2 (1.2, 1.2) 
IL-8 4 119.7 (38.1, 322.7) 5 82.8 (0.8, 261.1) 
IL-10 15 1.9 (1.9, 8.8) 15 1.9 (1.9, 1.9) 
IL-12p70 16 1.5 (1.5, 3.8) 18 1.5 (1.5, 1.5) 
TGF-β 
(ng/ml) 
0 43.9 (19.2, 61.8) 0 18.9 (16.1, 30.0) 
TNF 15 3.2 (3.2, 11.9) 17 3.2 (3.2, 3.2) 
IFN-γ 12 1.6 (1.6, 25.6) 15 1.6 (1.6, 6.7) 
Cytokine RNA (relative 
expression) 
CFS (n = 24) Control (n = 21) 
IL-1β RNA 0.42 (0.29, 0.60)  0.37 (0.32, 0.43) 
IL-6 RNA 0.00002 (0, 0.00003)  0.00001 (0, 0.00003) 
IL-8 RNA 0.05 (0.03, 0.11)  0.07 (0.04, 0.13) 
TGF-β RNA 0.40 (0.35, 0.53)  0.37 (0.32, 0.50) 
TNF RNA 0.41 (0.27, 0.51)  0.36 (0.26, 0.45) 
a = The only missing data was from one case of TGF-β. b = These values included the imputed 
lowest level of quantification (LOQ) score for a cytokine where a case had undetectable levels: 
this was repeated for all cytokine protein values. c = Constant at 1.2 as all undetectable, 
therefore no quartiles available. 
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Table 7: TGF-β assay values (pg/ml) by laboratory technician (medians; quartiles) 
 N TFG-β post-commuting p value 
Batch/Operator 1 
Patient 13 67833 (63066, 74606) 
0.686 
Control 2 63505 (56497, 70512) 
Batch 2 
Patient 11 22216 (20548, 26273) 
0.766 
Control 9 21361 (18683, 26376) 
Batch 3 
Patient 0 -- 
-- 
Control 10 19894 (14934, 27377) 
Operator 2 
Patient 11 22216 (20548, 26273) 
0.471 
Control 19 21298 (17361, 26554) 
Operator 1 vs Operator 2: Patient vs patient: p < 0.001; control vs control: p = 0.010 
